A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.
← catalyst calendarNCT07619131 · readout in 344 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
600estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-17 | estimated | When the study began enrolling |
| Primary completion | 2027-07-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-07-30 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hypercholesterolaemia
Interventions
- Drug: Laroprovstat
- Drug: Rosuvastatin 1
- Drug: Rosuvastatin 2
- Drug: Laroprovstat/Rosuvastatin 1
- Drug: Placebo to match rosuvastatin
- Drug: Placebo to match Laroprovstat and Laroprovstat/Rosuvastatin 1
- Drug: Laroprovstat/Rosuvastatin 2
- Drug: Placebo to match Laroprovstat/Rosuvastatin 2
Primary outcomes
what the primary-completion date above is the date OFRelative change in LDL-C at 8 weeks
measured 8 weeks
Relative change in LDL-C at 8 weeks
measured 8 weeks
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed